Literature DB >> 14627128

Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use.

Hideo Kuroki1, Takashi Morisaki, Kotaro Matsumoto, Hideya Onishi, Eishi Baba, Masao Tanaka, Mitsuo Katano.   

Abstract

For vaccinations based on dendritic cells (DCs), maturation of DCs is critical to the induction of T-cell responses. We tested the efficacy of streptococcal preparation OK-432 as a Good Manufacturing Practice (GMP)-grade maturation agent. OK-432 is currently used in Japan as a cancer immunotherapy drug. Immature monocyte-derived dendritic cells (imMo-DCs) isolated from human peripheral blood monocytes stimulated with granulocyte-macrophage colony stimulating factor and interleukin-4 were exposed to maturation factors, i.e., lipopolysaccharide (LPS), tumor necrosis factor alpha (TNF-alpha) plus prostaglandin E2 (PGE2), and OK-432 for 2 days. OK-432 increased expression of activation- and maturation-related molecules such as HLA-DR, CD80, CD83, and CD86 in imMo-DCs at levels similar to that of TNF-alpha plus PGE2, and higher than that of LPS. All agents examined induced allogeneic T-cell proliferation at a similar level. Only OK-432 caused significant production of interleukin-12 (IL-12) p70 and interferon gamma (IFN-gamma) at both the mRNA and protein levels in imMo-DCs. Neutralizing antibody against IL-12 p70 blocked IFN-gamma secretion from OK-432-stimulated Mo-DCs. IL-12 p70 produced by OK-432-stimulated imMo-DCs induced secretion of IFN-gamma by CD4+ T cells. OK-432 and LPS activated nuclear factor kappa B (NF-kappaB) in imMo-DCs. Both secretion of IL-12 p70 and IFN-gamma and activation of NF-kappaB induced by OK-432 were suppressed when imMo-DCs were pretreated with cytochalasin B. These results indicate that uptake of OK-432 by imMo-DCs is an early critical event for IL-12 p70 production and that NF-kappaB activation induced by OK-432 also contributes partially to IL-12 p70 production. In conclusion, OK-432 is a GMP-grade maturation agent and may be a potential tool for DC-based vaccine therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627128     DOI: 10.1007/s00262-003-0394-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  13 in total

1.  Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.

Authors:  C Venier; M D Guthmann; L E Fernández; L Fainboim
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 2.  Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations.

Authors:  Alexander G Raufi; Samuel J Klempner
Journal:  J Gastrointest Oncol       Date:  2015-10

3.  Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization.

Authors:  Y Nakamoto; E Mizukoshi; M Kitahara; F Arihara; Y Sakai; K Kakinoki; Y Fujita; Y Marukawa; K Arai; T Yamashita; N Mukaida; K Matsushima; O Matsui; S Kaneko
Journal:  Clin Exp Immunol       Date:  2010-11-19       Impact factor: 4.330

4.  Improved efficacy of therapeutic vaccination with viable human umbilical vein endothelial cells against murine melanoma by introduction of OK432 as adjuvant.

Authors:  Maolei Xu; Yun Xing; Ling Zhou; Xue Yang; Wenjun Yao; Wen Xiao; Chiyu Ge; Yanjun Ma; Jie Yang; Jie Wu; Rongyue Cao; Taiming Li; Jingjing Liu
Journal:  Tumour Biol       Date:  2013-03-01

5.  Inhibition of dendritic cell maturation by group A Streptococcus.

Authors:  Guadalupe Cortés; Michael R Wessels
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

Review 6.  Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.

Authors:  Takashi Morisaki; Kotaro Matsumoto; Hideya Onishi; Hideo Kuroki; Eishi Baba; Akira Tasaki; Makoto Kubo; Mitsunari Nakamura; Syoichi Inaba; Koji Yamaguchi; Masao Tanaka; Mitsuo Katano
Journal:  Hum Cell       Date:  2003-12       Impact factor: 4.174

7.  Mycobacterium tuberculosis whole cell lysate enhances proliferation of CD8 positive lymphocytes and nitric oxide secretion in the lungs of live porcine respiratory and reproductive syndrome virus vaccinated pigs.

Authors:  Cordelia Manickam; Varun Dwivedi; Jayla Miller; Tracey Papenfuss; Gourapura J Renukaradhya
Journal:  Viral Immunol       Date:  2013-01-11       Impact factor: 2.257

8.  Cytokine-based high log-scale expansion of functional human dendritic cells from cord-blood CD34-positive cells.

Authors:  Yui Harada; Yae Okada-Nakanishi; Yasuji Ueda; Shunichi Tsujitani; Satoru Saito; Terumi Fuji-Ogawa; Akihiro Iida; Mamoru Hasegawa; Tomohiko Ichikawa; Yoshikazu Yonemitsu
Journal:  Sci Rep       Date:  2011-11-29       Impact factor: 4.379

9.  Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles.

Authors:  S J Win; D G G McMillan; F Errington-Mais; V K Ward; S L Young; M A Baird; A A Melcher
Journal:  Br J Cancer       Date:  2011-12-01       Impact factor: 7.640

10.  Quality Verification with a Cluster-Controlled Manufacturing System to Generate Monocyte-Derived Dendritic Cells.

Authors:  Haruhiko Kawaguchi; Takuya Sakamoto; Terutsugu Koya; Misa Togi; Ippei Date; Asuka Watanabe; Kenichi Yoshida; Tomohisa Kato; Yuka Nakamura; Yasuhito Ishigaki; Shigetaka Shimodaira
Journal:  Vaccines (Basel)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.